|
WO2021062359A1
|
|
Methods for treating acute wounds and improving outcomes
|
|
AU2018211945A1
|
|
Tissue container systems
|
|
WO2014160000A1
|
|
Cryopreservation of viable human skin substitutes
|
|
US2010330046A1
|
|
Human skin substitutes expressing il-12
|
|
EP2352472A1
|
|
Dried and irradiated skin equivalents for ready use
|
|
EP2215212A1
|
|
Cold storage of organotypically cultured skin equivalents for clinical applications
|
|
CA2601595A1
|
|
Skin substitutes with improved purity
|
|
AU2006218610A1
|
|
Human skin equivalents expressing exogenous polypeptides
|
|
US2006141627A1
|
|
Vectors for stable gene expression
|
|
CA2758178A1
|
|
Human skin equivalents expressing exogenous polypeptides
|
|
EP3473102A1
|
|
Methods for providing human skin equivalents
|
|
AU2004247072A1
|
|
Room temperature storage of organs
|
|
AU2003254298A8
|
|
Species specific dna detection
|
|
CA2483547A1
|
|
Keratinocytes expressing exogenous angiogenic growth factors
|
|
CA2763666A1
|
|
Keratinocytes expressing exogenous angiogenic growth factors
|
|
AU2002255618B2
|
|
Improved skin substitutes and uses thereof
|
|
US6974697B2
|
|
Skin substitutes with improved barrier function
|
